Table 1. Summary table of the studies included in the article.
| References | Basal characteristics | LMCA PCI | LMCA SR | Outcomes |
| CPR: cardiopulmonary resuscitation; CS: cardiogenic shock; IABP: intra-aortic balloon pump; LAD: left anterior descending; LCX: left circumflex; LMCA: left main coronary artery; MACE: major adverse cardiovascular events; MI: myocardial infarction; MV: mechanical ventilation; NA: non-applicable; NSTEACS: non-ST-elevation acute coronary syndrome; OHCA: out-of-hospital cardiac arrest; PCI: percutaneous coronary intervention; SR: successful revascularization; ST: stent thrombosis; STEMI: ST-elevation myocardial infarction; TIMI: thrombolysis in myocardial infarction; TLR: target lesion revascularization; TVR: target vessel revascularization; UHT: urgent heart transplantation; VA-ECMO: venoarterial extracorporeal membrane oxygenation. | ||||
| Josiassen J, et al.[7] | n = 194, mean age: 69 yrs, male (73%), right coronary dominance (74%), multivessel intervention (44%), initial TIMI 0 flow (30%), IABP (20%), Impella (30%), VA-ECMO (10%), OHCA (22%) | 92% | 78% | 24-hour mortality: 39%
30-day mortality: 66% |
| Kim HS, et al.[8] | n = 15 | NA | NA | 100-day mortality: 73.3% |
| Homorodean C, et al.[9] | n = 40, initial TIMI 2/3 (67.5%), initial TIMI 0/1 and collaterals (12.5%)/no collaterals (20%) | 100% | NA | 30-day mortality: 60%
Initial TIMI 0/1: 84.6% vs. TIMI 2/3: 44% Initial TIMI 0/1 and no collaterals: 100% vs. TIMI 0/1 and collaterals: 60% |
| Higami H, et al.[10] | n = 115, mean age: 70 yrs, male (77%), femoral approach (75%), LMCA only (20%), initial TIMI ≤ 1 flow (22%), IABP (85%), VA-ECMO (26%) | 99% | NA
No-reflow/slow flow during PCI (26%) |
30-day mortality: 36.6%
180-day mortality: 49.5% |
| Édes IF, et al.[11] | n = 20, CPR (55%), IABP (35%), VA-ECMO (15%) | 100% | NA
Final TIMI 3 flow in LAD and LCX (70%) |
In-hospital mortality: 60%
CPR: 91% vs. no-CPR: 22% |
| Meraj PM, et al.[12] | n = 36, mean age: 70 yrs, male (77.8%), initial TIMI flow ≤ 1 (35%), cardiac arrest (44.4%), MV (72.2%), Impella 2.5® pre-PCI (55.6%), Impella 2.5® post-PCI (44.4%) | 100% | NA
TIMI flow 0 or 1 post-PCI (1.49%) |
In-hospital mortality: 61%
Impella 2.5® pre-PCI: 45% vs. Impella 2.5® post-PCI: 81.25% (P = 0.041) |
| Fuernau G, et al.[13] | n = 76, mean age: 69 yrs, male (87%), initial TIMI flow 0 (39%), IABP (53%), MV at admission (47%), CPR prior to admission (41%) | 92% | 87% | 30-day mortality: 49%
1-year mortality: 60% |
| Kawaji T, et al.[14] | n = 62 | 100% | NA | 30-day mortality: 54.8%
1-year mortality: 62.9% |
| Almudarra SS, et al.[15] | n = 545 including STEMI (n = 323) and NSTEACS (n = 222) | 100% | NA | 30-day mortality (STEMI and CS): 52%
1-year mortality (STEMI and CS): 61.1% No data of mortality in NSTEACS and CS |
| Kim U, et al.[16] | n = 42, mean age: 66 yrs, male (83.3%), IABP (69%) | 85.7% | NA | In-hospital mortality: 47.6%
1-year mortality: 50% |
| Parma A, et al.[17] | n = 30, IABP (100%) | 100% | NA | 30-day mortality: 63.3% |
| Hussain F, et al.[18] | n = 8, mean age: 62 yrs, male (75%), right coronary dominance (100%), complete revascularization (50%), thrombolysis pre-PCI (63%), MV (63%), CPR (50%), IABP (88%), VA-ECMO (25%), Impella 5.0® (12.5%) | 100% | 100% | In-hospital mortality: 38% |
| Pappalardo A, et al.[19] | n = 22, MV (45%), IABP (100%) | NA | NA | In-hospital mortality: 32% |
| Barone-Rochette G, et al.[20] | n = 17, mean age: 64 yrs, male (76%), right coronary dominance (82%), thrombolysis pre-PCI (29%), MV (41%), IABP (70%), VA-ECMO (41%) | 100% | 94% | In-hospital mortality: 29% |
| Pedrazzini GB, et al.[21] | n = 42 | 100% | NA | In-hospital mortality: 54.8% |
| Pepe M, et al.[22] | n = 13 | 100%
|
NA
|
In-hospital mortality: NA
30-day MACE (death, MI, TLR, TVR, ST, restenosis): 30.8% |
| Garcia-Alvarez A, et al.[23] | n = 12 | NA | 7% in UHT
22% in non-UHT |
In-hospital mortality: 75%
UHT: 25% |
| Jensen LO, et al.[24] | n = 29 | NA | NA | 30-day mortality: 51.7%
18-months mortality: 55.2% |
| Prasad SB, et al.[25] | n = 18 | 100% | NA | In-hospital mortality: 50% |
| Tan CH, et al.[26] | n = 11, mean age: 61 yrs, male (73%), multivessel disease (63%), IABP (100%) | 100% | 100% | In-hospital mortality: 63% |
| Barlis P, et al.[27] | n = 5, median age: 70 yrs, male (80%), initial TIMI flow 0−2 (60%) | 100% | 100% | In-hospital mortality: 60% |
| Bonello L, et al.[28] | n = 5, GpIIb/IIIa receptor antagonists (100%) | 100% | NA | In-hospital mortality: 40% |